Congenital Adrenal Hyperplasia
Also known as: CAH, Adrenogenital Syndrome
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive genetic disorders that affect the adrenal glands. These disorders result in the deficiency of enzymes involved in the synthesis of cortisol, aldosterone, or both. The most common form is caused by a deficiency of 21-hydroxylase, leading to virilization in females and salt-wasting crisis in severe cases.
Imagine your body has a factory that makes important hormones. In CAH, there's a problem in the factory, so it doesn't make enough of some hormones and makes too much of others. This can cause problems with how kids grow and develop, especially with their bodies looking different.
Signs & Symptoms
- Ambiguous genitalia in females
- Early puberty in males
- Rapid growth in childhood
- Short adult stature
- Salt-wasting crisis (dehydration, vomiting, diarrhea)
- Virilization (excessive hair growth, deepening of voice) in females
- Acne
- Infertility
Treatment Options
Glucocorticoid replacement therapy (Hydrocortisone, Prednisone, Dexamethasone)
HIGHLY EFFECTIVEMineralocorticoid replacement therapy (Fludrocortisone)
HIGHLY EFFECTIVESodium chloride supplementation (in salt-wasting forms)
HIGHLY EFFECTIVEReconstructive surgery (for ambiguous genitalia in females)
HIGHLY EFFECTIVEExperimental Gene Therapy
EXPERIMENTALDiagnosis
- Newborn screening (17-hydroxyprogesterone levels)
- Physical examination
- Hormone level testing (ACTH stimulation test)
- Genetic testing (CYP21A2 gene analysis)
- Pelvic ultrasound (in females)
- Karyotype analysis
History
The first descriptions of CAH date back to the late 19th century, with clearer understanding of the underlying hormonal imbalances emerging in the mid-20th century. The discovery of cortisol and its role in adrenal function, along with the identification of specific enzyme deficiencies, revolutionized the diagnosis and management of CAH.
Recent Breakthroughs
Development of Novel Glucocorticoids with Improved Safety Profiles
Research is focused on developing glucocorticoids with more targeted action and fewer side effects, such as bone loss and metabolic disturbances.
Gene Therapy Approaches for CAH
Early-stage clinical trials are exploring the potential of gene therapy to correct the underlying genetic defect in CAH, potentially offering a long-term cure.